This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Elan Corporation plc, Transition Therapeutics Inc.Elan and Transition Therapeutics Announce Modifications to ELND005 Phase II Clinical Trials in Alzheimer's Disease. Media Release: 15 Dec 2009. Available from: URL: http://www.elan.com
About this article
Cite this article
Nine patients die in phase II ELND 005 trial. React. Wkly. 1283, 3 (2010). https://doi.org/10.2165/00128415-201012830-00006
- Public Health
- Adverse Event
- Extension Study
- Dose Group